April 28, 2020 / 9:28 PM / a month ago

BRIEF-Merck - FDA Approves Merck’S Keytruda For Use At An Additional Recommended Dose Of 400 Mg Every Six Weeks For All Approved Adult Indications

April 28 (Reuters) - Merck & Co Inc:

* FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) FOR USE AT AN ADDITIONAL RECOMMENDED DOSE OF 400 MG EVERY SIX WEEKS FOR ALL APPROVED ADULT INDICATIONS

* MERCK & CO INC - NEW DOSAGE OPTION WILL BE AVAILABLE IN ADDITION TO CURRENT DOSE OF 200 MG EVERY THREE WEEKS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below